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Background: Adrenal insufficiency is a rare and potentially lethal disease if untreated. Several clinical signs and
biological markers are associated with glucocorticoid failure but the importance of these factors for diagnosing
adrenal insufficiency is not known. In this study, we aimed to assess the prevalence of and the factors associated
with adrenal insufficiency among patients admitted to an acute internal medicine ward.
Methods: Retrospective, case-control study including all patients with high-dose (250 μg) ACTH-stimulation tests
for suspected adrenal insufficiency performed between 2008 and 2010 in an acute internal medicine ward (n = 281).
Cortisol values <550 nmol/l upon ACTH-stimulation test were considered diagnostic for adrenal insufficiency. Area
under the ROC curve (AROC), sensitivity, specificity, negative and positive predictive values for adrenal insufficiency
were assessed for thirteen symptoms, signs and biological variables.
Results: 32 patients (11.4%) presented adrenal insufficiency; the others served as controls. Among all clinical and
biological parameters studied, history of glucocorticoid withdrawal was the only independent factor significantly
associated with patients with adrenal insufficiency (Odds Ratio: 6.71, 95% CI: 3.08 –14.62). Using a logistic regression,
a model with four significant and independent variable was obtained, regrouping history of glucocorticoid
withdrawal (OR 7.38, 95% CI [3.18 ; 17.11], p-value <0.001), nausea (OR 3.37, 95% CI [1.03 ; 11.00], p-value 0.044),
eosinophilia (OR 17.6, 95% CI [1.02; 302.3], p-value 0.048) and hyperkalemia (OR 2.41, 95% CI [0.87; 6.69], p-value
0.092). The AROC (95% CI) was 0.75 (0.70; 0.80) for this model, with 6.3 (0.8 – 20.8) for sensitivity and 99.2
(97.1 – 99.9) for specificity.
Conclusions: 11.4% of patients with suspected adrenal insufficient admitted to acute medical ward actually do
present with adrenal insufficiency, defined by an abnormal response to high-dose (250 μg) ACTH-stimulation test. A
history of glucocorticoid withdrawal was the strongest factor predicting the potential adrenal failure. The
combination of a history of glucocorticoid withdrawal, nausea, eosinophilia and hyperkaliemia might be of interest
to suspect adrenal insufficiency.
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Adrenal insufficiency is a relatively rare but potentially
lethal disease if missed during acute settings [1,2]. Symp-
toms, signs and biological markers associated with adrenal
failure are well known by clinicians [3,4]. However the
relative importance of these symptoms, signs and markers
has not been fully studied in patients admitted in acute
medical wards. Adrenal insufficiency is defined as primary
or secondary. Autoimmune and tuberculous adrenalitis
are the principal etiologies for primary adrenal failure,
which is characterized by low cortisol levels and elevated
plasma concentrations of ACTH. Impairment of the
hypothalamic-pituitary corticotropic axis is responsible for
secondary causes of adrenal insufficiency. These situations
are characterized by low circulating levels of cortisol and
ACTH. The most frequent cause of secondary adrenal
insufficiency is a tumour of the hypothalamic-pituitary
region but administration of supraphysiologic doses of
glucocorticoids may alter a normal hypothalamic response
with secondary adrenal failure once individuals are weaned
from the glucocorticoid treatment. Bilateral adrenalectomy
or drug-induced adrenal insufficiency may be considered as
iatrogenic etiologies for adrenal failure.
Symptoms commonly associated with adrenal insuffi-
ciency are “fatigue” (lack of energy or stamina), abdominal
pain, nausea, and dizziness (hypotension symptoms). The
patient history may include a key element related to pre-
vious glucocorticoid treatment, thus increasing the risk of
secondary adrenal failure related to glucocorticoid with-
drawal. Signs associated with adrenal insufficiency are low
blood pressure, vitiligo and/or skin changes. Biological mar-
kers of the disease include hyperkalemia, hyponatremia,
acidosis, hypercalcaemia and eosinophilia. Nevertheless, the
proportion of individuals with one or more symptoms or
signs associated with adrenal insufficiency is not clearly
described in the literature.
Evaluating adrenal function is a difficult task in clinical
practice [5]. Cortisol response to ACTH administration
may depend upon the biological stress of the patients (in-
tensive care versus stable conditions), the cut-off values for
cortisol levels and the use of low (1 μg) versus high
(250 μg) dose ACTH-stimulation test [6-9]. Basal cortisol
levels inaccurately assess adrenal function [10]. Conversely,
the high dose ACTH-stimulation test (“SynacthenW test”,
cosyntropin stimulation test or tetracosactide test) is gener-
ally accepted as reliable to evaluate adrenal function in
everyday practice, and considered as the easiest to perform
[11-13]. If this test is recognized as gold standard in various
clinical situations, it may be more difficult to define cut-off
values for cortisol levels in intensive care. Patel and co-
authors described expected values of basal serum cortisol
(> 250 nmol/l) and peak cortisol (> 600 nmol/l) after
250 μg intramuscular tetracosactrin in acute hospital
admissions [14]. However, the optimal cut-off for peakcortisol levels avec ACTH challenge has been questioned
by several authors and current recommendations seem to
include a minimum of > 18-20 μg/dl (> 500–550 nmol/l) to
consider the ACTH response as adequate. These normal
values vary dependent on laboratory and assay. In our de-
partment, the 550 nmol/l cut-off is considered as a normal
response to the ACTH challenge. The minimum increment
in serum cortisol is considered by Patel [14] and others as
invalid to diagnose adrenal failure, because individuals who
have a high basal concentration, due to normal circadian
rhytmicity or acute stress, may be unable to increase further
cortisol secretion.
The aim of this study was to identify the clinical and
biological determinants associated with adrenal insuffi-
ciency in patients admitted to an acute medical ward.
Methods
Study population
All patients admitted in a general internal ward of the
Lausanne University Hospital between 1st of January 2008
and 31st of December 2010 and requiring an ACTH-
stimulation test based upon clinical judgment were
included. This study was approved by the Institutional
Ethics Committee of the University of Lausanne.
Data collection
All patient files were reviewed, and information related to
a potential adrenal insufficiency as well as reasons to order
the ACTH-stimulation test were included in the analysis.
Symptoms collected were: fatigue, abdominal pain, nausea,
generalized weakness, hypotension symptoms such as dizi-
ness and/or history of glucocorticoid withdrawal. Physical
signs collected were: low blood pressure (<100 mmHg sys-
tolic and/or <50 mmHg diastolic blood pressure), vitiligo
and/or skin changes. Biological markers collected were:
hyperkalemia (> 5 mmol/l), hyponatremia (< 135 mmol/l),
acidosis (pH < 7.35), hypercalcaemia (total and ionized, cor-
rected calcium > 2.5 mmol/l) and eosinophilia (> 0.5 G/l).
Except for age, all other variables were coded as yes/no.
ACTH-stimulation test was considered as normal if any
value of cortisol was ≥ 550 nmol/l.
Statistical analysis
Statistical analysis was conducted using R (http://www.r-
project.org/) and Stata version 12 (Stata corp, College Sta-
tion, TX, USA). Results were expressed as number of
patients and (percentage) for qualitative data and as mean ±
standard deviation for quantitative data. Chi -square ana-
lysis was used to compare categorical data between
patients with abnormal ACTH-stimulation test and con-
trol group. A multivariate logistic regression analysis was
performed to determine which variables were independ-
ently associated with an abnormal ACTH-stimulation test.
Stepwise forward regression was used for model selection.
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nificance level for entry < 0.05, and a “broad” model, with
a significance level for entry <0.10. Results were expressed
as Odds ratio (OR) and 95% confidence interval (CI). The
performance of each model in discriminating between
patients and controls was assessed using the area under
the Receiver Operating Characteristic curve (AROC), the
sensitivity, the specificity, the positive and the negative
predictive values, with corresponding 95% CIs. Statistical
significance was established with P less than 0.05.
Results
Patient selection
During the 36 months of the survey, 11’310 patients
were hospitalized in the general internal ward. Among
them, 339 (2.9%) were clinically suspected of adrenal
insufficiency and had an ACTH-stimulation test. Unex-
plained signs such as hypotension, hyperkalemia, meta-
bolic acidosis or hyponatremia were the key signs used
by clinicians to order the ACTH-stimulation test in
most clinical situations. If adrenal failure was suspected,
the ACTH-test was performed and in most cases, stress
doses of glucocorticoid administrated for 48 hours. If
the short ACTH stimulation test was normal, the gluco-
corticoid treatment was immediately stopped. In the
proven 32 cases of adrenal failure, stress doses of hydro-
cortisone or prednisone were administrated and tapered.Table 1 Clinical characteristics of the patients with adrenal in
All
Number of patients 281
Women 132 (47.0)
Age (mean) 67 ± 16
Symptoms
Abdominal pain 35 (12.5)
Hypotension symptoms 12 (4.3)
Fatigue 48 (17.1)
Glucocorticoid withdrawal 53 (18.9)
Nausea 21 (7.5)
Generalized weakness 40 (14.2)
Signs
Eosinophilia 2 (0.7)
Low blood pressure 141 (50.2)
Vitiligo 2 (0.7)
Biological markers
Acidosis 7 (2.5)
Hypercalcaemia 10 (3.6)
Hyperkaliemia 35 (12.5)
Hyponatremia 87 (31.0)
Definitions: low blood pressure (<100 mmHg systolic and/or <50 mmHg diastolic b
hyperkalemia (>5 mmol/l), hyponatremia (<135 mmol/l), acidosis (pH <7.35), hyperc
(>0.5 G/l). Results are expressed as number of patients and (percentage). StatisticalAll patients with adrenal insufficiency left the hospital
under glucocorticoid treatment. Among these 339 patients,
6 (1.8%) were considered as false-positives as they were
under glucocorticoid treatment and 52 (15.3%) were
excluded because of missing information for at least one
study variable. The ACTH-stimulation test was normal in
these 52 individuals. The remaining 281 (82.9%) patients
(149 women and 132 men) were retained for analysis.
Patient characteristics
Among the 281 patients, 32 (11.4%) were abnormal
responders (blunted response to the ACTH-stimulation
test) while the remaining 249 (88.6%) were normal
responders and served as controls. The clinical and bio-
logical characteristics of the patients with adrenal insuf-
ficiency and the controls are summarized in Table 1. For
the 32 patients that had a confirmed adrenal failure,
ACTH levels were available for 8 patients. On those 8
patients, 6 (18.7%) combined low levels of cortisol and
elevated ACTH levels confirming the diagnostic of pri-
mary adrenal failure. The other 2 combined low levels of
cortisol and ACTH, confirming a secondary adrenal fail-
ure. The final suspected diagnosis was secondary adrenal
insufficiency for 26 patients (another 24 patients) (81.3%).
Profound adrenal failure was identified for 14 patients
(43.8% of all cases) with cortisol levels < 100 nmol/l. We
cannot rule out that several suspected cases of secondarysufficiency, versus control group
No adrenal
insufficiency
Adrenal
insufficiency
P value
249 32
113 (45.4) 19 (59.4) 0.19
68 ± 16 63 ± 15 0.10
30 (12.1) 5 (15.6) 0.57
12 (4.8) 0 (0.0) 0.37
40 (16.1) 8 (25.0) 0.31
36 (14.5) 17 (53.1) <0.001
16 (6.4) 5 (15.6) 0.07
33 (13.3) 7 (21.9) 0.19
1 (0.4) 1 (3.1) 0.22
125 (50.2) 16 (50.0) 0.87
1 (0.4) 1 (3.1) 0.22
7 (2.8) 0 (0.0) 1.00
10 (4.0) 0 (0.0) 0.61
28 (11.2) 7 (21.9) 0.09
80 (32.1) 7 (21.9) 0.31
lood pressure), vitiligo and/or skin changes. Biological markers collected were:
alcaemia (total and ionized, corrected calcium >2.5 mmol/l) and eosinophilia
analysis performed using chi-square or Fischer’s exact test.
Table 2 Variables associated with adrenal insufficiency
Odds-ratio 9%5 CI P value
Restricted model
Glucocorticoid withdrawal 6.66 [2.94 ; 15.09] <0.001
Nausea 3.48 [1.09 ; 11.14] 0.036
Broad model
Glucocorticoid withdrawal 7.38 [3.18 ; 17.11] <0.001
Nausea 3.37 [1.03 ; 11.00] 0.044
Eosinophilia 17.6 [1.02 ; 302.3] 0.048
Hyperkaliemia 2.41 [0.87 ; 6.69] 0.092
Results are expressed as Odds ratio and (95% confidence interval) for a yes vs.
no variable. Statistical analysis by stepwise forward logistic regression using a
significance value <0.05 (restricted model) or <0.10 (broad model) for entry. CI,
confidence interval.
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secondary since the ACTH levels were missing. However,
a history of glucocorticoid withdrawal within weeks or
months prior to the hospitalization was present in 13
patients (40.6%), a clinical situation highly suggestive of
secondary adrenal failure. All patients survived the acute
event and were treated by stress doses of glucocorticoids.
Six cases were excluded of the study considered as false
positive since under glucocorticoid treatment during the
ACTH-stimulation test. These patients had symptoms
and/or signs that were potentially associated with adrenal
insufficiency but none with adrenal crisis. The prevalence
of patients with basal cortisol < 165 nmol/l was of 8.9%
(25/281 patients). In the 32 individuals with blunted re-
sponse to the high-dose ACTH stimulation, the prevalence
of low basal cortisol was of 59.4% (19/32 patients). In
secondary adrenal insufficiency, the morning cortisol value
< 100 nmol/l may indicates adrenal failure. If this criteria
was used in our study, the prevalence of secondary adrenal
failure diagnosed was of 5.0% (14/281 patients) for the en-
tire cohort and of 43.8% (14/32 patients) for the proven
patients with adrenal failure on ACTH-stimulation test.
On bivariate analysis, history of glucocorticoid with-
drawal was the only variable that was significantly different
between responders and non-responders to ACTH: OR
6.71, 95% CI [3.08; 14.62]. The duration and the dose of
the treatment and the time elapsed between the end of the
treatment and the withdrawal was very variable between
the patients, and sometimes the information was lacking.
None of the abnormal responders were severly stressed,
based on C reactive protein, albumin or leucocytosis values.Table 3 Discrimination capacity of the restrictive and the
broad models
Restrictive model Broad model
AROC 0.717 (0.662–0.771) 0.753 (0.700–0.804)
Sensitivity (%) 3.1 (0.1–16.2) 6.3 (0.8–20.8)
Specificity (%) 99.6 (97.8–100) 99.2 (97.1–99.9)
Positive predictive value (%) 50.0 (1.3–98.7) 50.0 (6.8–93.2)
Negative predictive value (%) 88.9 (84.6–92.3) 89.2 (84.9–92.6)
Correctly classified (%) 87.3 88.6
Results are expressed as value and (95% confidence interval). AROC, area
under the receiver operating characteristic curve. Restrictive model:
glucocorticoid withdrawal and nausea; broad model: glucocorticoid
withdrawal, nausea, eosinophilia and hyperkalemia.Multivariate analysis of factors associated with adrenal
insufficiency
The variables significantly and independently associated
with adrenal insufficiency were assessed by forward step-
wise logistic regression using two significance levels for
entry (0.05 and 0.10) (Table 2). In the “restricted” model
(RM), only history of glucocorticoid withdrawal (OR
6.66, 95% CI [2.94; 15.09], p-value <0.001) and nausea
(OR 3.48, 95% CI [1.09; 11.14], p-value 0.036) were sig-
nificantly and independently associated with adrenal in-
sufficiency. In the “broad” model (BM), two more variables
were selected: eosinophilia (OR 17.6, 95% CI [1.02; 302.3],
p-value 0.048) and hyperkalemia (OR 2.41, 95% CI [0.87;
6.69], p-value 0.092) (with a history of glucocorticoid with-
drawal (OR 7.38, 95% CI [3.18 ; 17.11], p-value <0.001) and
nausea (OR 3.37, 95% CI [1.03 ; 11.00], p-value 0.044)).
The AROCs (95% CIs) were 0.72 (0.66; 0.77); 0.75 (0.70;
0.80) and 0.79 (0.70; 0.89) for the “restricted” model, the
“broad” model and the model with all variables, respectively
(p = 0.07) (Table 3). Sensitivity and specificity of the RM
were 3.1 (0.1 – 16.2) and 99.6 (97.8 – 100), respectively. Forthe BM, they were 6.3 (0.8 – 20.8) for sensitivity and 99.2
(97.1 – 99.9) for specificity.
In order to assess whether the stepwise model selection
was effective, we then performed a model comparison
between our models and new models created by adding
each time an extra variable (Additional file 1: Table S1).
There was not any substantial increase of the AROC, and
the differences were not significant, indicating that our
model selection was efficient.
Discussion
The administration of supraphysiologic doses of ACTH
(250 μg) is the standard challenge to test the adrenal re-
sponsiveness. This test has been widely used and several
studies have reported an excellent agreement between
peak cortisol concentrations obtained during the test
and in the gold standard insulin tolerance test [15,16].
The low-dose (1 μg) ACTH test has been proposed as a
more sensitive test to detect secondary adrenal failure.
When compared to the usual high dose ACTH test, the
1 μg stimulation test has demonstrated a slightly improved
sensitivity. However, the handling of the commercially
available ampoule of 250 mg of ACTH makes the test
more difficult to perform. Furthermore, it has been
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face of the injection devices and may blunt the anticipated
response [17].
Slightly over one out of ten (11.4%) patients with sus-
pected adrenal insufficient admitted in an acute medical
ward had an abnormal response to high-dose ACTH
stimulation test defined as a 550 nmol/l cut-off for corti-
sol. A low baseline cortisol (< 165 nmol/l) not responding
to ACTH is sometimes a recognized criteria to establish
adrenal insufficiency. Partial secondary adrenal insuffi-
ciency might be present in critically ill patients, character-
ized by a poor cortisol response to ACTH despite normal
baseline cortisol. A low cortisol increment (< 248 nmol/l)
was measured in 19.2% (54/281 patients) of the entire co-
hort and in 68.8% (22/32 patients) of the individuals with
proven adrenal failure. We cannot rule out that some
patients with low cortisol increment to the ACTH chal-
lenge may have some functional adrenal insufficiency.
However, this was probably not the case in our selected
population hospitalized in a general internal medicine
ward. All critically ill patients were excluded from the
study since these patients are directly admitted in the in-
tensive care unit of our institution. Low blood pressure
was present in half of patients in both cases with adrenal
insufficiency and controls. This sign was – in the design of
our study - not very useful to discriminate between
patients with or without adrenal insufficiency. Low blood
pressure remains a well recognized typical sign of acute
adrenal insufficiency but clinicians should of course rule
out other clinical diagnosis responsible for low blood pres-
sure [1,4].
Two multivariate models were analyzed. The “restricted”
model was composed of history of glucocorticoid with-
drawal and nausea, while the “broad” model included two
more variables, eosinophilia and hyperkalemia. Still, the
AROCs of both models did not differ, as they did not
differ from a model including all signs and symptoms.
Although the more parsimonious “restricted” model might
be preferred, its screening capacity is not optimal. Hence,
in order to maximise the likelihood of correctly diagnosing
adrenal insufficiency, clinicians should not rely their
judgement on the presence or absence of these two
criteria only. The diagnosis of adrenal failure is usually
obvious in patients with full-blown symptoms and signs
associated with acute glucocorticoid deprivation. However,
the diagnosis may be much more difficult in patients
admitted in an acute medical ward where multiple co-
morbidities are often present. Therefore, the clinician
judgement remains a critical step in the evaluation and
the “broad model” may therefore be more accurate.
Our study has several limitations. First, it was limited
to an acute general internal medicine ward and the esti-
mated prevalence might be different from other wards
such as intensive care units. Second, some cases mighthave been missed if the diagnosis was omitted, namely
where the test was not ordered. Finally, the plasma
ACTH values were not collected for all individuals and
we could not discriminate between primary and second-
ary adrenal insufficiencies. We also cannot rule out that
partial adrenal failure may have been missed in the con-
trols. The high dose ACTH test may identify only profound
adrenal failure but not partial and subtle corticotropic
failure that could have been detected in a low-dose (1 μg)
ACTH stimulation challenge.
Conclusion
11.4% of suspected adrenal insufficient patients admitted
to acute medical ward actually present with adrenal insuf-
ficiency, defined by an abnormal response to high-dose
(250 μg) ACTH-stimulation test.
Our results suggest that history of glucocorticoid with-
drawal is the factor most associated with adrenal insuffi-
ciency. The combination of a history of glucocorticoid
withdrawal, nausea, eosinophilia and hyperkalemia might
be of interest to suspect adrenal insufficiency.
Additional file
Additional file 1: Table S1. Effect of including additional variables in
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